{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:58:29Z","timestamp":1791082709351,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.maturitas.2013.03.014","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T07:31:34Z","timestamp":1368084694000},"page":"199-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Mechanism and novel therapeutic approaches to wasting in chronic disease"],"prefix":"10.1016","volume":"75","author":[{"given":"Nicole","family":"Ebner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitja","family":"Lainscak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Doehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.maturitas.2013.03.014_bib0005","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/07853890410017467","article-title":"Cardiac cachexia","volume":"36","author":"Anker","year":"2004","journal-title":"Annals of Medicine"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pharmthera.2008.09.009","article-title":"Cardiac cachexia: a systematic overview","volume":"121","author":"von Haehling","year":"2009","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","article-title":"Cachexia as a major underestimated and unmet medical need: facts and numbers","volume":"1","author":"von Haehling","year":"2010","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0167-5273(02)00233-4","article-title":"The syndrome of cardiac cachexia","volume":"85","author":"Anker","year":"2002","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0025","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ncpendmet0247","article-title":"The need for a standardized definition for cachexia in chronic illness","volume":"2","author":"Springer","year":"2006","journal-title":"Nature Clinical Practice Endocrinology & Metabolism"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0030","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clinical Nutrition"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/ncb0203-87","article-title":"Signalling pathways that mediate skeletal muscle hypertrophy and atrophy","volume":"5","author":"Glass","year":"2003","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0040","first-page":"15","article-title":"Cachexia versus sarcopenia","volume":"14","author":"Rolland","year":"2011","journal-title":"Current Opinion in Clinical Nutrition and Metabolic Care"},{"issue":"8","key":"10.1016\/j.maturitas.2013.03.014_bib0045","doi-asserted-by":"crossref","first-page":"702","DOI":"10.18632\/aging.100358","article-title":"Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia","volume":"3","author":"Hall","year":"2011","journal-title":"Aging"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1006\/cyto.1998.0398","article-title":"Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer","volume":"11","author":"Mart\u00edn","year":"1999","journal-title":"Cytokine"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0055","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1006\/bbrc.2001.4497","article-title":"The transcription factors NF-\u03baB and AP-1 are differentially regulated in skeletal muscle during sepsis","volume":"281","author":"Penner","year":"2001","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"10.1016\/j.maturitas.2013.03.014_bib0060","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.cardiores.2006.08.018","article-title":"Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure","volume":"73","author":"von Haehling","year":"2007","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0065","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.nutr.26.061505.111151","article-title":"Cancer-associated cachexia and underlying biological mechanisms","volume":"26","author":"Baracos","year":"2006","journal-title":"Annual Review of Nutrition"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0070","first-page":"1","article-title":"Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy","volume":"26","author":"Reed","year":"2011","journal-title":"FASEB Journal"},{"issue":"10","key":"10.1016\/j.maturitas.2013.03.014_bib0075","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.biocel.2005.03.010","article-title":"Ca(2+)-dependent proteolysis in muscle wasting","volume":"37","author":"Costelli","year":"2005","journal-title":"International Journal of Biochemistry and Cell Biology"},{"issue":"1","key":"10.1016\/j.maturitas.2013.03.014_bib0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13539-011-0049-z","article-title":"Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance","volume":"3","author":"Busquets","year":"2012","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0085","series-title":"Sarcopenia-age-related muscle wasting and weakness","first-page":"9","article-title":"Muscle wasting in cancer and ageing: cachexia versus sarcopenia","author":"Argiles","year":"2011"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0090","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa040933","article-title":"Myostatin mutation associated with gross muscle hypertrophy in a child","volume":"350","author":"Schuelke","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.maturitas.2013.03.014_bib0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13539-011-0035-5","article-title":"The role of myostatin in muscle wasting: an overview","volume":"2","author":"Elkina","year":"2011","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.maturitas.2013.03.014_bib0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s13539-011-0029-3","article-title":"IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia","volume":"2","author":"Schmidt","year":"2011","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0105","series-title":"Pharmacotherapy of cachexia","first-page":"117","article-title":"Diseases associated with cachexia: cancer","author":"Skipworth","year":"2006"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0110","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MCO.0b013e3283455e21","article-title":"Cancer cachexia therapy: a key weapon in the fight against cancer","volume":"14","author":"Coss","year":"2011","journal-title":"Current Opinion in Clinical Nutrition"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/ncponc0112","article-title":"Therapy insight: cancer anorexia\u2013cachexia syndrome \u2013 when all you can eat is yourself","volume":"2","author":"Laviano","year":"2005","journal-title":"Nature Clinical Practice Oncology"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0120","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","volume":"24","author":"Strasser","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nut.2005.06.003","article-title":"Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy","volume":"22","author":"Gramignano","year":"2006","journal-title":"Nutrition"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0130","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0140-6736(96)07015-8","article-title":"Wasting as independent risk factor for mortality in chronic heart failure","volume":"349","author":"Anker","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.maturitas.2013.03.014_bib0135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13539-012-0064-8","article-title":"European Palliative Care Research Collaborative (EPCRC) and the European Pharmacogenetic Study (EPOS), is there a genetic cause of appetite loss? \u2013 an explorative study in 1,853 cancer patients","volume":"3","author":"Solheim","year":"2012","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.maturitas.2013.03.014_bib0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13539-012-0061-y","article-title":"Recent developments in the treatment of cachexia: highlights from the 6th cachexia conference","volume":"3","author":"Ebner","year":"2012","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.maturitas.2013.03.014_bib0145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s13539-011-0046-2","volume":"2","author":"Coats","year":"2011","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.maturitas.2013.03.014_bib0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13539-011-0019-5","article-title":"Wasting in chronic kidney disease","volume":"2","author":"Mak","year":"2011","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.ki.5002585","article-title":"A proposed nomenclature and diagnostic criteria for protein\u2013energy wasting in acute and chronic kidney disease","volume":"73","author":"Fouque","year":"2008","journal-title":"Kidney International"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13539-011-0019-5","article-title":"Wasting in chronic kidney disease","volume":"2","author":"Mak","year":"2011","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0165","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-009-1427-z","article-title":"Inflammation and cachexia in chronic kidney disease","volume":"25","author":"Cheung","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1016\/j.maturitas.2013.03.014_bib0170","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10157-010-0340-x","article-title":"High-calorie diet with moderate protein restriction prevents cachexia and ameliorates oxidative stress, inflammation and proteinuria in experimental chronic kidney disease","volume":"14","author":"Kim","year":"2010","journal-title":"Clinical and Experimental Nephrology"},{"issue":"3","key":"10.1016\/j.maturitas.2013.03.014_bib0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s13539-011-0038-2","article-title":"Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle","volume":"2","author":"Cicoira","year":"2011","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00508-009-1194-7","article-title":"Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review","volume":"121","author":"Doehner","year":"2009","journal-title":"Wiener Klinische Wochenschrift"},{"issue":"Suppl (1)","key":"10.1016\/j.maturitas.2013.03.014_bib0185","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0954-6111(11)70005-1","article-title":"Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease","volume":"105","author":"Doehner","year":"2011","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0190","article-title":"COPD patient journey: hospitalisations as window of opportunity for extra-pulmonary interventions","author":"Lainscak","year":"2013","journal-title":"Current Opinion in Clinical Nutrition and Metabolic Care"},{"issue":"2","key":"10.1016\/j.maturitas.2013.03.014_bib0195","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13539-011-0023-9","article-title":"Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease","volume":"2","author":"Lainscak","year":"2011","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"issue":"Suppl (1)","key":"10.1016\/j.maturitas.2013.03.014_bib0200","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0954-6111(11)70009-9","article-title":"Mini nutritional assessment, body composition, and hospitalisations in patients with chronic obstructive pulmonary disease","volume":"105","author":"Benedik","year":"2011","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0205","doi-asserted-by":"crossref","DOI":"10.1152\/japplphysiol.00790.2012","article-title":"The mechanisms of cachexia underlying muscle dysfunction in COPD","author":"Remels","year":"2013","journal-title":"Journal of Applied Physiology"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1164\/rccm.201208-1441OE","article-title":"Central fat and peripheral muscle: partners in crime in chronic obstructive pulmonary disease","volume":"187","author":"van den Borst","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0215","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.rmed.2011.07.016","article-title":"Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease","volume":"106","author":"Ju","year":"2012","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0220","first-page":"553","article-title":"Schools AMWJ. Nutritinal targets to enhance exercise performance in chronic obstructive pulmonary disease","volume":"15","author":"van de Bool","year":"2012","journal-title":"Current Opinion in Clinical Nutrition and Metabolic Care"},{"issue":"9","key":"10.1016\/j.maturitas.2013.03.014_bib0225","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/euhj.1998.1446","article-title":"Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure","volume":"20","author":"Anker","year":"1999","journal-title":"European Heart Journal"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0230","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0235","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/hrt.82.3.352","article-title":"Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure","volume":"82","author":"Murdoch","year":"1999","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.maturitas.2013.03.014_bib0240","first-page":"171","article-title":"Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia","volume":"185","author":"Sarraf","year":"1997","journal-title":"Journal of Emergency Medical Services"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0245","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/eurjhf\/hfp046","article-title":"Adiponectin is increased in cardiac cachexia irrespective of body mass index","volume":"11","author":"Araujo","year":"2009","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0250","first-page":"185","article-title":"Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure","volume":"3","author":"Van Berendoncks","year":"2010","journal-title":"Circulation: Heart Failure"},{"issue":"3","key":"10.1016\/j.maturitas.2013.03.014_bib0255","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/eje.0.1480293","article-title":"The role of the novel adipocyte-derived hormone adiponectin in human disease","volume":"148","author":"Diez","year":"2003","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0260","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MED.0b013e3283469505","article-title":"Hormonal consequences and prognosis of chronic heart failure","volume":"18","author":"Attanasio","year":"2011","journal-title":"Current Opinion in Endocrinology, Diabetes and Obesity"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0265","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1517\/13543784.14.2.163","article-title":"Future prospects of anticytokine therapy in chronic heart failure","volume":"14","author":"von Haehling","year":"2005","journal-title":"Expert Opinion in Investigational Drugs"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0270","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.clnu.2010.06.003","article-title":"Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia","volume":"29","author":"Busquets","year":"2010","journal-title":"Clinical Nutrition"},{"issue":"2","key":"10.1016\/j.maturitas.2013.03.014_bib0275","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1634\/theoncologist.2009-0153","article-title":"Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia","volume":"15","author":"Mantovani","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0280","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1200\/JCO.2004.06.024","article-title":"An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a north central cancer treatment group and national cancer institute of canada collaborative effort","volume":"22","author":"Jatoi","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0285","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1200\/JCO.1993.11.1.152","article-title":"Body-composition changes in patients who gain weight while receiving megestrol acetate","volume":"11","author":"Loprinzi","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.maturitas.2013.03.014_bib0290","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.maturitas.2013.03.014_bib0295","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ncpendmet0120","article-title":"Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging","volume":"2","author":"Bhasin","year":"2006","journal-title":"Nature Clinical Practice Endocrinology & Metabolism"},{"issue":"3","key":"10.1016\/j.maturitas.2013.03.014_bib0300","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13539-011-0040-8","article-title":"Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?","volume":"2","author":"Thum","year":"2011","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.maturitas.2013.03.014_bib0305","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3945\/ajcn.2010.28608E","article-title":"Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting","volume":"91","author":"Gullett","year":"2010","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0310","unstructured":"World Anti Doping Agency. The 2011 Prohibited List. 2011. Available from: http:\/\/www.wada-ama.org\/Documents\/World_Anti-Doping_Program\/WADP-Prohibited-list\/To_be_effective\/WADA_Prohibited_List_2011_EN.pdf."},{"key":"10.1016\/j.maturitas.2013.03.014_bib0315","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1021\/jm9806648","article-title":"Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071)","volume":"42","author":"Hamann","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0320","first-page":"222","article-title":"Novel non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile","volume":"2","author":"Rosen","year":"2002","journal-title":"Journal of Musculoskeletal & Neuronal Interactions"},{"issue":"8","key":"10.1016\/j.maturitas.2013.03.014_bib0325","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s11095-006-9024-3","article-title":"Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands","volume":"23","author":"Gao","year":"2006","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0330","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1210\/en.2005-0572","article-title":"Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats","volume":"146","author":"Gao","year":"2005","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.maturitas.2013.03.014_bib0335","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1124\/jpet.108.146811","article-title":"Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator","volume":"328","author":"Vajda","year":"2009","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0340","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1152\/ajpendo.00440.2010","article-title":"17\u03b2-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate","volume":"300","author":"Yarrow","year":"2011","journal-title":"American Journal of Physiology, Endocrinology and Metabolism"},{"issue":"3","key":"10.1016\/j.maturitas.2013.03.014_bib0345","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","article-title":"The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial","volume":"2","author":"Dalton","year":"2011","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.maturitas.2013.03.014_bib0350","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13539-011-0017-7","article-title":"l-carnitine and cancer cachexia: clinical and experimental aspects","volume":"2","author":"Silverio","year":"2011","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.maturitas.2013.03.014_bib0355","first-page":"7","article-title":"MT-102, a new \u201canabolic catabolic transforming agent\u201d improves heart function in a rat model of cancer cachexia","volume":"3","author":"P\u00f6tsch","year":"2012","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0360","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.yfrne.2009.10.008","article-title":"Ghrelin in the regulation of body weight and metabolism","volume":"31","author":"Castaneda","year":"2010","journal-title":"Frontiers in Neuroendocrinology"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0365","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0014-2999(02)02552-9","article-title":"Effects of ghrelin and amylin on dopamine, norepinephrine and serotonin release in the hypothalamus","volume":"454","author":"Brunetti","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0370","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/hc3601.095575","article-title":"Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure","volume":"104","author":"Nagaya","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0375","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0167-0115(03)00117-4","article-title":"Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure","volume":"114","author":"Nagaya","year":"2003","journal-title":"Regulatory Peptides"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0380","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1471-4892(03)00013-4","article-title":"Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure","volume":"3","author":"Nagaya","year":"2003","journal-title":"Current Opinion in Pharmacology"},{"issue":"2","key":"10.1016\/j.maturitas.2013.03.014_bib0385","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13539-010-0011-5","article-title":"Ghrelin for cachexia","volume":"1","author":"Akamizu","year":"2010","journal-title":"Journal of Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0390","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1378\/chest.99.6.1495","article-title":"The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease","volume":"99","author":"Pape","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.maturitas.2013.03.014_bib0395","unstructured":"http:\/\/www.helsinn.com\/Institutional.aspx?Root=212&L2=232&L3=274&L4=272&Lingua=EN (accessed 13.03.13)."},{"key":"10.1016\/j.maturitas.2013.03.014_bib0400","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020264s017lbl.pdf [accessed 13.03.13]."},{"key":"10.1016\/j.maturitas.2013.03.014_bib0405","unstructured":"http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVand.AIDSActivities\/ucm117940.htm Serostim (somatropin), new drug application (NDA) 20-604 for the treatment of AIDS wasting or cachexia [accessed 13.03.13]."},{"key":"10.1016\/j.maturitas.2013.03.014_bib0410","doi-asserted-by":"crossref","first-page":"8E","DOI":"10.1016\/j.amjcard.2008.02.065","article-title":"Cachexia: common, deadly, with an urgent need for precise definition and new therapies","volume":"101","author":"Lainscak","year":"2008","journal-title":"American Journal of Cardiology"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851221300087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851221300087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:56:33Z","timestamp":1759913793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037851221300087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S037851221300087X"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2013.03.014","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism and novel therapeutic approaches to wasting in chronic disease","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2013.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}